Physician profile
Beverly Smith
NPI 1033609979
$1,573.44
in general payments reported to CMS, 2019-2025
23 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $332 · 2023: $328 · 2024: $294 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $348.14 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $204.16 | 2022 | |
| Lilly USA, LLC | $197.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $196.26 | 2024-2025 | |
| Novo Nordisk INC | $81.91 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $77.93 | 2025 | |
| Phathom Pharmaceuticals, INC. | $66.11 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $57.87 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.00 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $42.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $41.62 | 2025 | |
| Merck Sharp & Dohme LLC | $32.90 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $24.24 | 2021 | |
| Krystal Biotech INC | $20.63 | 2024 | Vyjuvek |
| Dexcom, INC. | $19.84 | 2025 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $16.31 | 2023 | |
| Amgen INC. | $14.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.03 | 2023 | Jardiance, Synjardy, Tradjenta |
| Dynavax Technologies Corporation | $12.42 | 2024 | Heplisav-B |
| Ibsa Pharma INC. | $11.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.